Profile data is unavailable for this security.
About the company
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
- Revenue in USD (TTM)11.00m
- Net income in USD-111.08m
- Incorporated2004
- Employees55.00
- LocationCara Therapeutics Inc400 Atlantic Street, Suite 500STAMFORD 06901United StatesUSA
- Phone+1 (203) 406-3700
- Fax+1 (203) 567-1510
- Websitehttps://www.caratherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lotus Pharmaceuticals Inc | 70.79m | 1.72m | 10.24m | 233.00 | 0.0687 | 0.0011 | 2.65 | 0.1446 | 0.0553 | 0.0553 | 2.56 | 3.58 | 0.6321 | 37.27 | 17.85 | 303,836.90 | 1.55 | 22.84 | 1.71 | 26.40 | 35.10 | 41.62 | 2.45 | 19.93 | 0.4428 | 30.80 | 0.0516 | 0.00 | 28.71 | 31.70 | -12.22 | 51.11 | 70.48 | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 11.84m | 1.00 | -- | 0.0661 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| Aptorum Group Ltd | 431.38k | -2.82m | 11.90m | 3.00 | -- | 0.4536 | -- | 27.59 | -0.9126 | -0.9126 | 0.0954 | 4.80 | 0.0208 | 30.36 | 3.88 | 143,793.30 | -20.92 | -40.45 | -19.62 | -42.36 | 2.45 | -4.04 | -1,006.30 | -1,233.68 | 1.18 | -- | 0.1694 | -- | -66.71 | 2.38 | 71.18 | -- | -78.15 | -- |
| Cadrenal Therapeutics Inc | 0.00 | -6.24m | 12.37m | 3.00 | -- | 3.10 | -- | -- | -5.88 | -5.88 | 0.00 | 3.74 | 0.00 | -- | -- | 0.00 | -138.35 | -- | -173.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.47 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | -17.24m | 12.44m | 2.00 | -- | 0.471 | -- | -- | -1.93 | -1.93 | 0.00 | 4.92 | 0.00 | -- | -- | 0.00 | 0.5012 | -7.42 | 0.5333 | -7.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -299.38 | -- | -- | -- |
| Guardion Health Sciences Inc | 6.43m | -5.93m | 14.04m | 9.00 | -- | 1.02 | -- | 2.18 | -4.61 | 4.97 | 5.04 | 10.71 | 0.4467 | 2.74 | 8.20 | 714,121.10 | -41.22 | -77.90 | -45.86 | -86.55 | 44.86 | 42.45 | -92.26 | -176.93 | 16.59 | -2.98 | 0.00 | -- | 10.85 | 67.03 | 101.00 | -- | -58.56 | -- |
| Aytu Biopharma Inc | 93.76m | -13.68m | 14.63m | 150.00 | -- | 0.4432 | -- | 0.1561 | -2.65 | -2.65 | 18.21 | 5.53 | 0.6792 | 2.42 | 2.93 | 625,053.30 | -9.91 | -33.56 | -25.58 | -52.81 | 65.32 | 56.89 | -14.60 | -73.81 | 0.6923 | 0.216 | 0.352 | -- | 11.10 | 96.56 | 84.33 | -- | -- | -- |
| Talphera Inc | 398.00k | -13.70m | 15.62m | 15.00 | -- | 1.23 | -- | 39.25 | -0.6353 | -0.6323 | 0.0185 | 0.7491 | 0.0187 | -- | -- | 26,533.33 | -64.37 | -22.60 | -78.11 | -28.55 | -- | -- | -3,443.22 | -714.87 | -- | -- | 0.00 | -- | -- | -21.26 | -119.16 | -- | -34.33 | -- |
| DH Enchantment Inc | 100.00 | -173.19k | 16.09m | 1.00 | -- | -- | -- | 160,915.00 | -0.0002 | -0.0002 | 0.00 | -0.0012 | 0.0438 | 0.1493 | -- | 100.00 | -7,579.43 | -- | -- | -- | 0.00 | -- | -173,190.00 | -- | 0.0029 | -14.85 | -- | -- | -95.43 | -- | 59.53 | -- | -- | -- |
| Cara Therapeutics Inc | 11.00m | -111.08m | 16.56m | 55.00 | -- | 1.43 | -- | 1.51 | -2.04 | -2.04 | 0.2017 | 0.2115 | 0.1063 | 1.10 | 2.10 | 199,927.30 | -107.38 | -35.76 | -132.61 | -40.82 | 74.66 | -- | -1,010.20 | -162.10 | 4.48 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Cumberland Pharmaceuticals, Inc. | 37.79m | -10.38m | 17.20m | 91.00 | -- | 0.6521 | -- | 0.4551 | -0.7328 | -0.7328 | 2.67 | 1.87 | 0.4501 | 0.8643 | 3.17 | 415,225.80 | -12.35 | -7.03 | -17.75 | -9.52 | 82.58 | 79.95 | -27.45 | -17.64 | 1.26 | -38.85 | 0.382 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
| Nexgel Inc | 5.01m | -3.39m | 18.54m | 19.00 | -- | 4.16 | -- | 3.70 | -0.5722 | -0.5722 | 0.8464 | 0.6589 | 0.4942 | 3.03 | 6.44 | 263,631.60 | -35.74 | -44.61 | -48.15 | -56.19 | 23.74 | 5.02 | -72.33 | -180.98 | 0.8135 | -- | 0.1992 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
| TherapeuticsMD Inc | 996.00k | -4.83m | 19.72m | 1.00 | -- | 0.7127 | -- | 19.80 | -0.4348 | -0.5538 | 0.0889 | 2.40 | 0.0212 | -- | 0.5048 | 996,000.00 | -10.31 | -53.35 | -13.13 | -111.61 | 45.08 | 86.67 | -485.34 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
| Cyclo Therapeutics Inc | 1.13m | -20.74m | 20.37m | 8.00 | -- | -- | -- | 17.99 | -0.9104 | -0.9104 | 0.0474 | -0.1785 | 0.242 | 0.4002 | 13.16 | 141,553.80 | -443.08 | -132.22 | -- | -215.17 | 91.56 | 90.37 | -1,831.29 | -1,114.04 | 0.4283 | -- | -- | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
| China Health Industries Holdings, Inc. | 95.95k | -1.36m | 21.30m | 32.00 | -- | -- | -- | 221.99 | -0.0208 | -0.0208 | 0.0015 | -0.0366 | 0.0037 | 0.5035 | 20.57 | 2,998.44 | -5.18 | 3.04 | -6.89 | 3.66 | -5.34 | 69.55 | -1,419.49 | 28.61 | 0.0377 | -- | 1.76 | -- | 41,225.93 | -55.72 | -15.49 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Cara Therapeutics Inc's reporting currency: US Dollar USD
22.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 2.23m | 4.07% |
| Disciplined Growth Investors, Inc.as of 30 Jun 2024 | 1.94m | 3.53% |
| Chescapmanager LLCas of 30 Jun 2024 | 1.70m | 3.10% |
| Farallon Capital Management LLCas of 30 Jun 2024 | 1.56m | 2.84% |
| BNP Paribas Financial Marketsas of 30 Jun 2024 | 1.08m | 1.96% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 1.07m | 1.94% |
| Two Sigma Advisers LPas of 30 Jun 2024 | 861.60k | 1.57% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 718.44k | 1.31% |
| Millennium Management LLCas of 30 Jun 2024 | 586.76k | 1.07% |
| Geode Capital Management LLCas of 30 Jun 2024 | 472.69k | 0.86% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
